PEMAZYRE
Identification of Pemazyre
| No description |
Google image searchProduct monograph
Active ingredient
pemigatinib, 13.5 MG
DIN: 02519968
Dosage form(s): TABLET
Route(s) of administration: ORAL
Schedule: Prescription
Company: INCYTE CORPORATION
Date: 26-NOV-2021
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01E — PROTEIN KINASE INHIBITORS (ATC, ATC/DDD)
- L01EN — Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors (ATC, ATC/DDD)
- L01EN02 — PEMIGATINIB (ATC/DDD)
Reference brand drug: Pemazyre
